go-v.orgdoi

Can mouse models of cancer reliably improve clinical trial outcome?

Grit Sophie Herter-Sprie, Kwok‐Kin Wong · Clinical Investigation · 2013

  • DOI 10.4155/cli.12.149
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

One of the major threats humankind faces today is cancer. Incidences of neoplasia worldwide are estimated to translate to 13 million cancer deaths by 2030. Despite promising response rates through treatment modalities such as surgical resection as well as chemo- and radiation therapy in a few cancer entities, we still lack sufficient therapeutics that provide long-term survival in cancer patients, especially in patients with advanced disease. Hence, accelerated translation of highly encouraging in vitro and in vivo preclinical therapeutic findings is urgently needed to meet the demand for novel cancer drugs to combat cancer mortality successfully.

Genetically engineered mouse models recapitulating characteristics of human disease have become an indispensable tool in cancer research to predict clinical outcome. This commentary highlights current benefits and limitations of developing novel mouse models of cancer to subsequently improve clinical trial outcome in humans.

Open the resolved locator · 10.4155/cli.12.149

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 02:26 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.12.149
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.